The widely anticipated FDA approval of Genentech’s CD20-targeting antibody Ocrevus (ocrelizumab) for treating both relapsing and primary progressive forms of multiple sclerosis (MS), on March 28, marks the beginning of a new era in MS therapy…
Click here to original publication.
Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 5 MAY 2017 393, 394